Caliber Wealth Management LLC KS Buys New Position in Eli Lilly and Company (NYSE:LLY)

Key Points

• Caliber Wealth Management LLC acquired a new stake in Eli Lilly and Company, purchasing 707 shares valued at approximately $584,000.
• Institutional investors own an impressive 82.53% of Eli Lilly's stock, indicating strong hedge fund interest in the company.
• Eli Lilly has announced a quarterly dividend of $1.50 per share, with an annualized yield of 0.74%, set to be paid on September 10th.

Caliber Wealth Management LLC KS bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 707 shares of the company's stock, valued at approximately $584,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Prudent Investors Network Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter valued at $731,000. Assetmark Inc. grew its position in shares of Eli Lilly and Company by 5.6% in the first quarter. Assetmark Inc. now owns 44,978 shares of the company's stock valued at $37,148,000 after purchasing an additional 2,383 shares during the period. USAdvisors Wealth Management LLC grew its position in shares of Eli Lilly and Company by 6.3% in the first quarter. USAdvisors Wealth Management LLC now owns 286 shares of the company's stock valued at $236,000 after purchasing an additional 17 shares during the period. Elefante Mark B purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at $486,000. Finally, Cetera Investment Advisers grew its position in shares of Eli Lilly and Company by 5.9% in the first quarter. Cetera Investment Advisers now owns 246,287 shares of the company's stock valued at $203,411,000 after purchasing an additional 13,689 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LLY. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Trading Down 4.7%

Shares of LLY stock traded down $38.20 during trading hours on Tuesday, reaching $769.91. The company had a trading volume of 3,635,747 shares, compared to its average volume of 3,756,908. The company has a 50 day moving average of $773.01 and a 200 day moving average of $800.67. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The firm has a market cap of $729.67 billion, a price-to-earnings ratio of 62.53, a P/E/G ratio of 1.18 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company's revenue was up 45.2% on a year-over-year basis. During the same quarter last year, the business earned $2.58 earnings per share. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.78%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.